99 related articles for article (PubMed ID: 16885345)
1. Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging.
Hamstra DA; Bhojani MS; Griffin LB; Laxman B; Ross BD; Rehemtulla A
Cancer Res; 2006 Aug; 66(15):7482-9. PubMed ID: 16885345
[TBL] [Abstract][Full Text] [Related]
2. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.
Gottlieb E; Haffner R; King A; Asher G; Gruss P; Lonai P; Oren M
EMBO J; 1997 Mar; 16(6):1381-90. PubMed ID: 9135153
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
[TBL] [Abstract][Full Text] [Related]
4. The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage.
Magrini R; Russo D; Fronza G; Inga A; Menichini P
J Cell Biochem; 2007 Apr; 100(5):1276-87. PubMed ID: 17063487
[TBL] [Abstract][Full Text] [Related]
5. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity.
Pant V; Xiong S; Jackson JG; Post SM; Abbas HA; Quintás-Cardama A; Hamir AN; Lozano G
Genes Dev; 2013 Sep; 27(17):1857-67. PubMed ID: 23973961
[TBL] [Abstract][Full Text] [Related]
6. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model.
Wang W; El-Deiry WS
Cancer Biol Ther; 2003; 2(2):196-202. PubMed ID: 12750563
[TBL] [Abstract][Full Text] [Related]
7. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
8. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
10. Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells.
Tinkum KL; Marpegan L; White LS; Sun J; Herzog ED; Piwnica-Worms D; Piwnica-Worms H
Mol Cell Biol; 2011 Sep; 31(18):3759-72. PubMed ID: 21791610
[TBL] [Abstract][Full Text] [Related]
11. In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation.
Chin PL; Momand J; Pfeifer GP
Oncogene; 1997 Jul; 15(1):87-99. PubMed ID: 9233781
[TBL] [Abstract][Full Text] [Related]
12. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
[TBL] [Abstract][Full Text] [Related]
13. p53-independent induction of rat hepatic Mdm2 following administration of phenobarbital and pregnenolone 16alpha-carbonitrile.
Nelson DM; Bhaskaran V; Foster WR; Lehman-McKeeman LD
Toxicol Sci; 2006 Dec; 94(2):272-80. PubMed ID: 17000718
[TBL] [Abstract][Full Text] [Related]
14. Oscillatory Dynamics of p53-Mdm2 Circuit in Response to DNA Damage Caused by Ionizing Radiation.
Zhang Y; Liu H; Li Z; Miao Z; Zhou J
IEEE/ACM Trans Comput Biol Bioinform; 2020; 17(5):1703-1713. PubMed ID: 30762566
[TBL] [Abstract][Full Text] [Related]
15. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
16. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
Moumen A; Masterson P; O'Connor MJ; Jackson SP
Cell; 2005 Dec; 123(6):1065-78. PubMed ID: 16360036
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene.
Liang H; Lunec J
Gene; 2005 Nov; 361():112-8. PubMed ID: 16202543
[TBL] [Abstract][Full Text] [Related]
18. The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents.
Gillet R; Grimber G; Bennoun M; Caron de Fromentel C; Briand P; Joulin V
Oncogene; 2000 Jul; 19(31):3498-507. PubMed ID: 10918608
[TBL] [Abstract][Full Text] [Related]
19. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice.
Bouvard V; Zaitchouk T; Vacher M; Duthu A; Canivet M; Choisy-Rossi C; Nieruchalski M; May E
Oncogene; 2000 Feb; 19(5):649-60. PubMed ID: 10698510
[TBL] [Abstract][Full Text] [Related]
20. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
